Application of portfolio optimization to drug discovery by Yevseyeva, Iryna et al.
Application of portfolio optimization to drug discovery1
Iryna Yevseyeva1,3, Eelke B. Lenselink2, Alice de Vries3,2
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Abstract9
In this work, a problem of selecting a subset of molecules, which are poten-
tial lead candidates for drug discovery, is considered. Such molecule subset
selection problem is formulated as a portfolio optimization, well known and
studied in financial management. The financial return, more precisely the
return rate, is interpreted as return rate from a potential lead and calculated
as a product of gain and probability of success (probability that a selected
molecule becomes a lead), which is related to performance of the molecule,
in particular, its (bio-)activity. The risk is associated with not finding active
molecules and is related to the level of diversity of the molecules selected in
portfolio. It is due to potential of some molecules to contribute to the diver-
sity of the set of molecules selected in portfolio and hence decreasing risk of
portfolio as a whole. Even though such molecules considered in isolation look
inefficient, they are located in sparsely sampled regions of chemical space and
are different from more promising molecules. One way of computing diversity
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of a set is associated with a covariance matrix, and here it is represented by
the Solow-Polasky measure. Several formulations of molecule portfolio opti-
mization are considered taking into account the limited budget provided for
buying molecules and the fixed size of the portfolio. The proposed approach
is tested in experimental settings for three molecules datasets using exact
and/or evolutionary approaches. The results obtained for these datasets
look promising and encouraging for application of the proposed portfolio-
based approach for molecule subset selection in real settings.
Keywords: Portfolio Approach, Multicriteria optimization, Decision10
Support, Drug Discovery11
1. Introduction12
When searching for the most promising drug like molecules for a drug13
discovery project, usually, de novo drug discovery uses in vitro experiments14
(colloquially called “test-tube experiments”). For this, circa 100 promising15
molecules are selected from a database and typically only circa 1 percent of16
the molecules are tested successfully in vitro, that is they become so called17
lead molecules [4]. High-throughput screening (HTS) allows for testing a18
large number of molecules by robotized machines using advanced laboratory19
equipment. However, testing in vitro is an expensive process and cannot al-20
ways be applied to all possible projects, even though in industry millions of21
molecules can be screened if the target is interesting enough. To reduce costs,22
HTS can be complemented by preliminary in silico (performed via computer23
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simulation) virtual screening (VS). VS approaches [27] are used to pre-select24
molecules from virtual libraries or large databases of commercially available25
molecules (e.g. ZINC [13]) based on their chemical properties. Selection is26
typically done based on the assessment of the success probability of candidate27
molecules using either a compound-based method or a target-based method28
or a combination of both. Typically, no explicit economical information is29
taken into account and simple methods like clustering are applied. The suc-30
cess probability is not given directly, but in the form of a score corresponding31
to (bio-)activity that is proportional to it.32
A typical scenario in a pharmaceutical research laboratory is that a33
chemist selects a subset from a large vendor database of molecules (e.g.34
ZINC) and orders these. Each molecule has a price, and the budget of the35
chemist is limited, but it has to be allocated for buying molecules. That36
is, money not spent cannot be used for another purpose (and, thus, will be37
lost). Note that here we do not look into experimental planning and drug38
production, see e.g. [1], which is a separate subject of research.39
Classical approaches for selecting promising molecules are based on pre-40
dicted activity score. However, selecting molecules based on their perfor-41
mance (success probabilities / activity scores) only is not enough and even42
risky. It is due to a high probability of selecting well-performing, but similar43
molecules, which all might be unsuccessful for the same reason.44
An alternative approach is to take into account diversity of selected sub-45
sets of molecules. However, selection purely based on diversity will neglect46
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the information about activity given to the chemists by VS models. More-47
over, price might also play a role in the choice as it influences the number48
of molecules that can be bought given a limited budget. Hence, existing,49
just clustering- or just scoring-based selection models are not sufficient for50
handling these problems.51
In this work, we consider the first stage of drug discovery of identifying52
lead candidates with an approach which takes into account performance of53
molecules according to their predicted (bio-) activity and diversity of selected54
molecules simultaneously. Similar approach was taken in [17], where activity55
score and diversity were maximized at the same time. Here, the molecule56
subset selection problem is considered and modeled by analogy with a well-57
known financial portfolio selection problem, see e.g. [5]. A similar binary58
problem of finding an optimal combination of items subject to constraints59
is known in operations research as the knapsack problem, see e.g. [16]. Ac-60
cording to the portfolio optimization approach when selecting a subset of61
molecules to be tested in vitro, in addition to choosing molecules with high-62
est performance values (and maximizing the average quality of the selected63
subset of molecules), the molecules with the most dissimilar structures should64
be considered. The former aspect contributes to maximizing the quality of65
the selected subset of molecules and the latter one corresponds to maximizing66
the diversity of such a subset.67
The financial portfolio return, more precisely the return rate, is inter-68
preted as the return rate from a potential lead and calculated as a prod-69
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uct of the gain and the probability of success (probability that a selected70
molecule becomes a drug in the end), which is related to the performance71
of the molecule, in particular, its (bio-)activity. The risk is associated with72
not finding active molecules when choosing a portfolio and is related to the73
level of diversity of the molecules in the portfolio. The diversity can be ex-74
pressed as a covariance matrix used by Solow and Polasky [23] for measuring75
diversity of a biological population. Interestingly, as an example of a utili-76
tarian approach to the biological diversity preservation, Solow and Polasky77
indicated the potential utility in future from one of the preserved species as78
a cure of some yet unknown disease (see [23]).79
Some molecules, when considered in isolation look inefficient, but as part80
of a portfolio may contribute to the decreasing risk of a portfolio as a whole81
and may be included in a portfolio as they are located in sparsely sampled82
regions of chemical space and are different from more promising molecules.83
In addition, the limited budget provided for buying molecules and the fixed84
size of the portfolio are taken into account in the introduced drug portfolio85
model as constraints.86
This article is structured as follows: In the next section 2, we consider87
the general (multiobjective) formulation of the (financial) portfolio selection88
problem and, then, in section 3, we model the lead subset selection problem as89
portfolio optimization. In section 4, we propose algorithms to solve portfolio90
selection formulations, and in section 5, we discuss results obtained for three91
molecule datasets. Finally, in section 6, we draw conclusions and indicate92
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directions for future research.93
2. Related Work94
2.1. Portfolio selection as a multi-objective optimization problem95
The most-widely used formulation of portfolio selection problem was de-96
veloped by Markowitz early in the 50s [15]. It addresses a way of selecting97
a combination of several assets called portfolio that collectively would be of98
the best quality and be as diverse as possible. Hence, portfolio optimiza-99
tion should simultaneously satisfy two conflicting goals, minimizing risk and100

















xi ∈ [0, 1], i = 1, . . . , NTotal,
where NTotal is the number of assets; xi is the proportion of money invested102
in the asset i; ri is the expected return (per period) of the asset i; and qij is103
the real-valued covariance of expected returns of the assets i and j.104
As a result of optimizing this problem not a single portfolio but a set105
of portfolios are selected that are optimal with respect to the two specified106
objectives.107
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For this problem the search space of portfolios S is [0, 1]NTotal . The set of108
feasible portfolios F is the subset of portfolios in S with
∑NTotal
i= xi = 1. We109
consider two real valued objective functions defined on S, σ2(x) = x>Qx and110
E(x) = r>x. Each portfolio x is associated with a 2-dimensional evaluation111
vector in the objective space, (σ2(x), E(x))>, where the risk objective is to112
be minimized and the return objective is to be maximized.113
Optimizing two or more conflicting objectives simultaneously is referred114
to as Multiobjective Optimization (MOO). The portfolio selection problem115
formulated as in (1) is bi-objective: Minimizing the risk and maximizing116
the expected return should be taken into consideration and optimized at the117
same time. These objectives are generally in conflict with each other and118
finding a portfolio with minimal risk and maximal return simultaneously is119
infeasible. Hence, decreasing risk for a portfolio can be obtained at the cost120
of lowering its return only.121
Interestingly, including some assets, which look inefficient when consid-122
ered in isolation, may benefit the portfolio as a whole, since they contribute123
to decreasing the risk of a portfolio when considered in combination with124
other assets. This is due to their location in sparsely sampled regions of125
search space and their difference from more promising assets. Cost of assets126
may also be taken into account as a separate objective, but we included it127
in the return (which is reduced by the costs invested in initial assets) and in128
the budget constraint.129
Recently, the principles of portfolio optimization have been successfully130
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applied not only for optimizing financial portfolio selection [24], but also in131
other domains, such as strategic decision making [14] (for instance, team132
management), projects selection [11], IT project portfolio management [3],133
and evolutionary algorithms selection [29]. For instance, for evolutionary134
algorithms selection it is important to keep good, but different individuals,135
which should avoid fast convergence of the population to a single individual136
or few similar individuals. Hence, the selection procedure should simultane-137
ously optimize quality and diversity of population. In [29], a multiobjective138
evolutionary algorithm based on the portfolio selection idea was introduced139
and results comparable to the results of the state-of-the-art algorithms were140
obtained.141
2.2. A posteriori Markowitz model142
The general idea of the a posteriori approach to solving MOO problems143
rephrased in terms of portfolios is: first, to compute the set of efficient (or144
non-dominated) portfolios and, then, to select a single portfolio from it. The145
selection of a final portfolio can be done by the decision maker or expert,146
e.g. with the help of multi-criteria decision aiding approaches, see e. g. [2].147
Given two objective functions, in our case σ2(x) = x>Qx and E(x) = r>x,148
one can associate to each solution x a 2-dimensional evaluation vector in the149
objective space, (σ2(x), E(x))>, where the risk objective is to be minimized150
and the return objective is to be maximized; r and Q are defined as before151
in (1).152
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A portfolio x(1) dominates a portfolio x(2) (in symbols x(1) ≺ x(2)), if153
and only if E(x(1)) ≥ E(x(2)) and (σ2(x(1)) < σ2(x(2)) or E(x(1)) > E(x(2)))154
and σ2(x(1)) ≤ σ2(x(2)). The efficient set XE (of portfolios) is given by the155
portfolios that are not dominated by any other portfolio. The image of this156
set is called the Pareto front PF , i. e.157
PF = {(y1, y2)> ∈ R2 | ∃x ∈ XE : y1 = σ2(x) and y2 = E(x)}.
An example of Pareto fronts of optimal portfolios can be seen in Figure158
4. Note that we chose the first coordinate (y1) for the risk objective (or159
variance), and the second coordinate (y2) for the expected return objective,160
thereby following the convention in portfolio optimization.161
It should be noted that here the formulation (1) is adapted from the162
continuous version to a discrete, in particular an integer one. In integer163
adaptation an asset is either taken or not at a fixed price. The search space164
of the problem S is {0, 1}NTotal .165
The Pareto front will be obtained at the upper left boundary of the166
set of attainable solutions Y = {(y1, y2)> ∈ R2 | ∃x ∈ {0, 1}NTotal : y1 =167
σ2(x) and y2 = E(x)}. It can, for instance, be obtained by a series of con-168
strained single objective optimization problems. Moreover, a fixed budget169
B is allocated for buying assets of a portfolio, which in research projects is170
lost if not spent. Hence, the integer adaptation of the Markowitz model is as171
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follows:172






> · c ≤ B;
xi ∈ {0, 1}, i = 1, . . . , NTotal,
where ci refers to the cost of an asset, which can be different for different173
assets.174
The set of feasible portfolios F is now the subset of portfolios in S with175 ∑NTotal
i=1 cixi = x
> · c ≤ B.176
Earlier VS for drug discovery was formulated as a multiobjective opti-177
mization problem in [17], where both activity and diversity were maximized178
simultaneously. Our portfolio-based formulation is similar, however, different179
diversity measure based on Solow-Polasky diversity [23] is used, see section180
3.2, and expected return based on activity is computed instead of activity181
score maximization.182
2.3. A priori Sharpe ratio model183
All portfolios belonging to the efficient set present tradeoffs between re-184
turn and risk. Eventually however, from the set of efficient portfolios a single185
one should be chosen. Instead of letting the decision maker make a subjec-186
tive decision by viewing solutions on the Pareto front (a posteriori decision187
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making) one could also establish beforehand a criterion by which the best188
solution on the Pareto front is selected (a priori decision making).189
The investment management suggests a large number of measures to eval-190
uate return-to-risk ratios of portfolios, relatively to time period (e. g., stan-191
dard deviation), to market behavior (e. g., beta ratio), to benchmark asset192
(e. g., tracking error, excess return, Sharpe ratio). The Sharpe ratio, also193
called reward-to-volatility ratio, is the most widely used risk-adjusted per-194
formance index [5] and will be used here.195
The Sharpe ratio can be defined with the help of the capital allocation line196
(CAL). It is a straight line on the return-risk graph (see Figure 1) that shows197
all possible combinations of risky portfolios with the risk-free asset rf ≥ 0.198
The risk-free asset, rf , has a return that is smaller than the minimal expected199
return of an efficient portfolio rf < rmin, and it assumes risk-free investment.200
The optimal CAL corresponds to the portfolios with lowest risk for any given201
value of return r > rf . The slope of the optimal CAL is a sub-derivative of202
the function that defines the Pareto front of efficient portfolios. The point203
at which the CAL touches the front of efficient portfolios corresponds to the204
Sharpe ratio that provides an optimal risky portfolio.205
Here, the risk free investment is chosen to be rf = −B, as this will be







Figure 1: Sharpe ratio on intersection of CAL and Pareto front
The Sharpe ratio characterizes how well the return of a portfolio compensates206
the risk taken, and it measures excess of return per unit of risk. When207
comparing two portfolios, the one with the higher Sharpe ratio gives more208
return per risk. Finding the portfolio with maximal Sharpe ratio yields the209




s.t. x> · c ≤ B;
xi ∈ {0, 1}, i = 1, . . . , NTotal,
where B refers to the budget, which in research projects if not spent is lost.211
2.4. Portfolios with fixed size212
The problem with the Markowitz (2) and optimal Sharpe ratio (3) for-213
mulations is that they both favor selection of empty portfolios as they may214
be best at minimizing risk of any losses. One way to neutralize this effect215
is to require a fixed number of assets to be selected into the portfolio. This216
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problem formulation is referred to as fixed size portfolio selection and it as-217
sumes that the number of assets to be selected is limited to a specific number218
NPortfolio. Then, in addition to the formulation (2) or (3), a constraint of the219
following form is assumed:220
x> · e = NPortfolio,
where e is in {0, 1}NTotal ; each coordinate is either 0 or 1, summing up to221
portfolio of NPortfolio size (with NPortfolio << NTotal not all molecules being222
selected in portfolio out of NTotal).223
This formulation is equivalent to the 0-1 quadratic knapsack problem.224
Problems of this form were intensively studied in the literature due to their225
simple and practical formulation, but there are difficulties in finding exact226
solutions for them (as indicated in [16] and [20]).227
3. Drug subset selection as portfolio optimization228
Several formulations from the previous section can be used for selecting229
portfolio of molecules that are potential drugs. For formulating such prob-230
lems the following model variables are considered:231
1. A fixed budget B is available and has to be spent. Money that is not232
used will be lost.233
2. Each successful molecule is associated with a gain G, which is the value234
(expressed in monetary units) gained if the molecule becomes a drug.235
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The gain is the same for each successful molecule Gi = G and is zero236
for unsuccessful molecules.237
3. For each available molecule i = 1, . . . , NTotal a probability of success pi238
is given or obtained a priori.239
4. For each candidate molecule i = 1, . . . , NTotal the cost ci for buying240
and testing it is known. The cost of different molecules may vary241
significantly, and this cost does not involve indirect costs, e. g. costs of242
the in vitro testing.243
5. From a given set of NTotal candidates, a subset of NPortfolio molecules244
is selected such that245
(a) the budget B is not exceeded.246
(b) The expected return E is to be maximized, where the expected247
return is given by the expected value of the random variable of248
the return R of a portfolio of molecules selected for testing.249
(c) The risk σ associated with the expected return is to be minimized.250
3.1. A posteriori Markowitz model with fixed size portfolio251
The problem corresponding to a posteriori Markowitz model with limited252
budget and fixed size of portfolio constitutes a two-objective optimization253
problem that is formulated as follows:254
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E(x) → max; (4)
σ2(x) → min;
s.t. x> · c ≤ B;
x> · e = NPortfolio;
xi ∈ {0, 1}, i = 1, . . . , NTotal,
and is referred in the text as the Markowitz model with fixed size portfolios.255
Here, xi, i = 1, . . . , NTotal, denote the decision variables; xi = 1 means256
that the i-th molecule is selected and xi = 0 means that it is not selected;257
NTotal is the number of available molecules. The search space of the problem258
S is {0, 1}NTotal . The set of feasible portfolios F is now the subset of portfolios259
in S with
∑NTotal
i=1 xi = NPortfolio, where NPortfolio is the size of the portfolio.260
We consider two real valued objective functions defined on S, σ2(x) = x>Qx261
and E(x) = r>x. Each portfolio x is associated with a 2-dimensional evalu-262
ation vector in the objective space, (σ2(x), E(x))T , where the risk objective263
is to be minimized and the return objective is to be maximized; r and Q are264
defined as before in (1).265
The computation of return E(x) and risk σ2(x) is discussed next. The
return E(x) is defined as the gains minus the losses. For the expected return
it is important to realize that money from the budget that is not invested in
molecules is lost. Therefore, the losses will be B and the gains will be the
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cumulated gains from molecules that become successful drugs. Hence,







Due to the probabilistic nature of the return (we get it only in case of
successful drug(s)), it can be modeled as a random variable. Let x̃i denote
a random variable of Bernoulli type that models the uncertain return on





, return rate with probability pi in case of success;
0− ci
ci
= −1, return rate with probability 1− pi in case of no success.








Following the classical model of Markowitz, the risk σ2(x) can be ex-266
pressed by means of a covariance matrix Q as follows:267






where qij is a correlation between the return from the i-th molecule ri and268
the return from the j-th molecule rj. The computation of the covariance on269
the basis of a distance matrix will be derived from the Solow-Polasky model270
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as discussed in the next section.271
3.2. Solow-Polasky diversity measure272
One possible interpretation of the covariance can be done using a measure273
for estimating diversity of a (biological) population introduced by Solow and274
Polasky (see [23]). Originally, they were searching for a measure that can be275
used for evaluating population diversity rigorously, assuming some particular276
properties for this measure are respected. A measure which counts essentially277
different species and is used in the context of species preservation. Within278
the utilitarian model of Solow and Polasky the more species is considered279
to be more useful because of e.g. their potential future medical benefits. In280
general there are other reasons for species preservation, e.g. for stability of281
eco-system or ethical reasons. But in our context utilitarian motivation for282
species preservation fits well.283
Hence, they suggested a diversity function:284
D(s) = e>F (s)−1e,
where e is an NTotal-vector of 1’s and F (s) is a non-singular NTotal-by-NTotal285
distance matrix F (s) = [f(d(si, sj))], with a distance function f(dij) taken286
for each pair of species d(si, sj). Each entry of the Solow-Polasky matrix287
indicates distance between species si and sj, where i = 1, . . . , NTotal and288
j = 1, . . . , NTotal.289
When compared to other diversity measures, e.g. proposed in [28], Solow-290
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Polasky distance takes into account not only the distance between species in291
the population but also provides a measure for the number of different species292
in it. This model is inspired by probabilistic modeling of a set of species, but293
can be adapted to drug discovery.294
Let S = {s1, s2, . . . , sNTotal} be a set of molecules, |S| = NTotal. Let S ′ be295
any subset of S, then B(S ′) denotes the composite event that at least one296
molecule in S ′ is successful. By Pr(B(S ′)) we denote the probability of this297
composite event. The expected benefit of S ′ can be measured by the product298
Pr(B(S ′)) ·V , where V is a fixed unit value of benefit. Based on this benefit299
measure different subsets of S can be compared.300
Knowing a priori information on the performance of different molecules301
with respect to the specified goal(s), the probability of their benefit can be302
defined as Pr(Bi) = pi, where Bi denotes the event that the i-th molecule is303
successful. Otherwise, if probabilities are unknown, they may be considered304
as equal Pr(Bi) = p for all Bi, i = 1, . . . , NTotal. For the event Bj being305
successful, the conditional probability for the event Bi is defined in [23] as306
Pr(Bi|Bj) = p+(1−p)f(dij), where f is a function selected with the following307
properties: f(0) = 1, f(∞) = 0, f ′ ≤ 0. Here, as remarked by Solow and308
Polasky, f can be interpreted as a correlation function.309
Finding the NTotal-variate distribution Pr(B(S)) from univariate and bi-310
variate probabilities is not possible. However, the lower bound on it was311
defined in [10]. One example of the distance function for computing this312
distance matrix is provided in [23]: f(d) = e−θd(si,sj), and it will be used313
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here.314
3.3. A posteriori Markowitz model with Solow-Polasky diversity315
In addition to difficulties with computing an exact solution for a fixed316
size portfolio, in some cases the tendency of selecting the cheapest solutions317
in the portfolio may be observed if enough diversity is reached at the cost of318
cheapest assets. Hence, relaxing the constraint on the number of assets in319
the portfolio may be beneficial.320
Fortunately, Solow and Polasky specified a set of requirements which a321
biological diversity measure should satisfy; see [23] for more details. One322
of the requirements is monotonicity in species, which suggests that the di-323
versity of a set increases with adding new elements to it and decreases with324
removing elements. This property is taken into account in the next portfolio325
optimization model.326
Since minimizing risk of selecting similar assets into a portfolio can also be327
interpreted as maximizing diversity of selected portfolio of assets, different328
formulations of diversity can be taken in the portfolio selection problem.329
Here, we propose to use Solow-Polasky diversity as a second objective instead330
of the risk measure calculated as a variance of the returns.331
The Solow-Polasky diversity measure is calculated as the sum of the en-332
tries of the inverse of the correlation matrix for selected assets:333







where F (x)−1ij is the inverse of the correlation matrix for all selected assets.334
Then, the two objectives to be optimized are: the return and the diversity335
of the portfolio, which can be presented in the following model:336
E(x) → max; (5)
D(x) → max;
s.t. x> · c ≤ B;
xi ∈ {0, 1}, i = 1, . . . , NTotal.
Even though both a posteriori approaches use the correlation function sug-337
gested by Solow and Polasky, the Markowitz model minimizes the sum of338
the correlation matrix entries, while the Solow-Polasky diversity model max-339
imizes the sum of the entries of the inverse of the correlation matrix. Hence,340
the former model favors smaller size portfolios, while the latter one gives341
preference to larger portfolios.342
4. Solution algorithms343
Different methods can be used to compute efficient portfolios to the given344
portfolio selection problem. In this section, the methods that proved to be345
robust solvers are presented. In general, the difficulty of finding efficient346
portfolios depends on the number of candidate molecules NTotal and the size347
of the subset that is selected NPortfolio.348
Portfolio optimization problems belong to the class of NP hard problems349
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and, under the P 6= NP assumption, the effort needed to solve them ex-350
actly is growing exponentially with increasing NTotal. Portfolio optimization351
problems can be formulated either as discrete or continuous/parametric op-352
timization problems. The former presentation is more common due to faster353
performance on small and medium size problems (with up to 500 assets) with354
interior-point optimizers. However, in [24], it was shown that for large-scale355
problems (in the range of 1,000 to 3,000 assets) continuous formulation may356
be computationally more efficient when solved with some optimizers. Re-357
cently, new exact solvers such as Gurobi (see [12]) show fast performance for358
large instances (at least with datasets with up to 5,000 assets considered in359
this work) with branch and bound method.360
However, for finding the Pareto fronts in Markowitz models and com-361
puting Sharpe ratio, some adaptations to the formulations presented earlier362
need to be performed before applying exact solvers. This will be discussed363
next, first for the Pareto front computation in the Markowitz model with364
fixed size portfolio and then for the Sharpe ratio maximization. For the case365
of the Markowitz model with Solow-Polasky diversity optimization instead366
of the original risk objective, exact solvers cannot be applied due to the367
complexity of the risk objective function. But approximate algorithms, such368
as meta-heuristics and multiobjective evolutionary algorithms in particular,369
could and will be applied to find approximate solutions.370
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4.1. Markowitz model with fixed size portfolio computation using ε-constraint371
method372
To find the Pareto front and efficient set of the problem, it is proposed373
to use the ε-constraint method, see e.g. [18]. This is done by formulating a374
series of single objective constrained optimization problems (SOCOPs) with375
moving constraint on one of the objective function values. Then one objective376
is optimized subject to the other objective fixed and expressed as a constraint.377
To obtain, sayNPareto, points on the Pareto front, we solve the following series378
of NPareto SOCOPs for ascending expected returns Ej, j = 1, . . . , NPareto:379
σ2(x) → min; (6)
s.t. E(x) ≥ Ej;
x> · c ≤ B;
x> = NPortfolio;
xi ∈ {0, 1}, i = 1, . . . , NTotal.
The resulting optima will be called x∗j , and their risk σ
2∗
j and return E
∗
j380
values. The values of E∗j are taken evenly spaced between lower bound E
min
381
and upper bound Emax. The computation of the lower and upper bounds,382
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Emin and Emax, is done by solving the SOCOPs, respectively:383
E(x) → min; (7)
s.t. x> · c ≤ B;
xi ∈ {0, 1}, i = 1, . . . , NTotal,
and384
E(x) → max; (8)
s.t. x> · c ≤ B;
xi ∈ {0, 1}, i = 1, . . . , NTotal.
Let xmin denote the solution obtained for the first problem (7) and xmax385
denote the solution obtained for the second problem (8). Then, the lower386
bound for the return is Emin = E(xmin) and the upper bound for the return387
is Emax = E(xmax).388
4.2. Sharpe ratio with fixed size portfolio computation using quadratic pro-389
gramming390
In order to maximize the Sharpe ratio, it would be beneficial to get rid of391
the nonlinear and non-quadratic term
E(x)−rf
σ(x)
in the problem formulation (3),392
and then use a quadratic solver. For this, homogenization has been suggested393
in [5]. However, our experience was that the resulting mixed integer quadratic394
programming (QP) problem was difficult to solve due to resulting covariance395
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matrix being not of a semidefinite type.396
Alternatively, it is also possible to compute the Pareto front with (1) and
find the point on the Pareto front that maximizes the Sharpe ratio computed
with (3). Given a sufficiently dense approximation of the Pareto front this is
accomplished by evaluating the Sharpe ratio of all points on the Pareto front
i.e.:
xsharpe = arg max{Sh(x1), . . . , Sh(xNPareto)}.
It is important in this context that points that maximize the Sharpe ratio397
are part of the efficient set.398
4.3. Markowitz model with Solow-Polasky diversity computation using multi-399
objective genetic algorithms400
In case of Markowitz model with Solow-Polasky diversity considered as401
a risk objective (5), the need of obtaining the inverse of the distance matrix402
makes the application of quadratic programming difficult. An alternative ap-403
proach is to use approximate methods, for instance, meta-heuristics. While404
meta-heuristics do not guarantee reaching an optimal solution, they can typ-405
ically obtain good approximations to optima fairly quickly even for NP hard406
combinatorial problems, which is the case of knapsack / portfolio optimiza-407
tion problems considered in this work.408
Among many meta-heuristics developed so far, multiobjective evolution-409
ary algorithms (MOEAs) are particularly common for solving multi-objective410
optimization problems. In this study, two common MOEAs are considered:411
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NSGA-II (see [6]) and SMS-EMOA (see [7]). Using otherwise standard imple-412
mentations of these meta-heuristic solvers, we introduce two problem specific413
adaptations. These are the mutation and the recombination operators, which414
were specifically designed for the subset selection problem.415
MOEAs maintain a population (multi-set) of individuals that is changing416
over time due to the application of variation and selection operators. From a417
given population P (t) at time t pairs of parents are selected – in the so-called418
mating selection step – and offspring are then generated by recombination419
and mutation based on these parents. Then from the offspring and the420
individuals of previous population P (t) a set of individuals is selected – in421
the so-called environmental selection step – that forms the next population422
P (t+1). While the two selection steps are based on choosing individuals with423
the best objective function values, the two variation steps – recombination424
and mutation – seek to generate new individuals that resemble some of the425
traits of their parents. Recombination combines the information of parents,426
and mutation does a small random modification of a solution.427
The NSGA-II and SMS-EMOA algorithms differ in their selection steps:428
In NSGA-II, a new offspring population of the same size as the population429
P (t) is generated, and, subsequently, the new population P (t + 1) is se-430
lected based on so-called non-dominated sorting and crowding-distance. In431
SMS-EMOA, only one offspring is generated based on P (t) and the next432
population P (t+ 1) is obtained by non-dominated sorting and selecting the433
subset that maximizes the hypervolume indicator. Here, the hypervolume in-434
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dicator, which the SMS-EMOA seeks to maximize, is a measure computed to435
show how well a population serves to mark the boundary between the dom-436
inated and non-dominated spaces, and, thus, how well it serves to represent437
the true Pareto front. The MOEA for the portfolio subset selection problems438
represents individuals (that are portfolios) as sorted index lists. For instance,439
the sequence (1, 4, 6, 29) represents the portfolio that selects the 1st, the 4th,440
the 6th and the 29th molecules.441
The mutation is done by (1) deleting a single randomly chosen molecule442
from the portfolio, (2) adding a randomly chosen new molecule, and (3)443
replacing a molecule inside the portfolio by a molecule outside the portfolio.444
Each of these mutation operators is applied with a certain probability for each445
molecule, which is denoted by pMD, pMA, and respectively pMR. In case of a446
fixed number of molecules in the portfolio, only replacement is used. While447
pMD and pMA determine probability of adding and deleting a single molecule448
per portfolio, the replacement probability pMR is defined per molecule in the449
portfolio.450
As a recombination operator m-point crossover is applied. This means451
we randomly select m points for the number of molecules. After each point452
we change the parent we use to copy from. To make it applicable for subsets,453
the subset membership is interpreted as a bit-string (one means a molecule is454
a member of portfolio, zero means a molecule is not a member of portfolio),455
and the crossover determines membership based on either one of the two456
parents selected randomly. The probability of crossover is pCO. If crossover457
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is not applied, then one of the two parents chosen randomly is copied and458
will serve as offspring (before mutation).459
5. Experimental results460
5.1. Molecular portfolio selection model assumptions461
First, the information on a covariance matrix Q needs to be formulated.462
In chemistry, the distance between molecules can be defined by evaluating463
similarities/differences in the structure of two molecules. Being able to mea-464
sure the distance d(xi, xj) between each pair of molecules i and j, provides465
means for defining the matrix F (x) of NTotal-by-NTotal size, e.g. as suggested466
in [23] with elements fij = e
−θd(xi,xj), where θ is set to θ = 0.5. The distance467
between molecules can be computed based on their similarity, e.g. according468
to the Tanimoto similarity, see [25] also used in [22].469
Tanimoto similarity SimT is a measure of similarity between two bit470
vectors A and B. The bit-vectors used here are the molecular fingerprints.471
A molecular fingerprint is a bit vector, where each bit represents whether a472
chemical substructure is part of the molecule (1) or not (0). The Tanimoto473






where the index z corresponds to a particular property of molecule structure.475
In this study, circular fingerprints (FCFP4) calculated with Pipeline476
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Pilot 9.0.2.1 were used [21]. To predict activity of molecules, we used a477
Proteochemometric model as published by van Westen et al. in [26]. The478
molecules selected here originated from the Enamine building blocks [8] with479
prices defined per 100mg.480
Then, we can calculate the distance between two molecules as a dissimi-481
larity measure, which is diversity:482
d(xi, xj) = 1− SimT , (9)
where SimT is Tanimoto similarity.483
Second, the information on (bio-)activities of the candidate molecules484
needs to be translated into success probabilities. Activity ai is normally485
given as logarithmized activity li; in this case, we can use ai = e
li .486
Moreover, from experience chemists know an average probability of suc-487
cess p̄, for the sake of the argument estimated as p̄ = 1/100. Let us consider488
a vector of NTotal activities (exponentiated) A = {a1, . . . , aNTotal} and let489
P = {p1, . . . , pNTotal} denote the success probabilities. Then, the average490








and we know that activities are proportional to success probability. Hence,492
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for some constant k it holds:493
pi = k ∗ ai, ∀i = 1, . . . , NTotal. (11)
By substituting pi in (10) as defined in (11), we can obtain k:494
k = p̄ ∗ NTotal∑NTotal
i=1 ai
. (12)
Combining 11 and 12 we get:495




Third, the gain from a new lead compound (i.e. a molecule that may496
lead to a new drug) may vary between, e.g. GL = 10, 000 and GU = 100, 000497
USD.498
Fourth, several findings for the current drug portfolio selection model are499
based on the analysis of these model assumptions. Since the return of each500
molecule, which is equal to the product of gain and probability of success501
(for GL ri = 10, 000 ∗ 0.0001 = 1 or for GU ri = 100, 000 ∗ 0.0001 = 10), is502
very small, it turns out that it is not profitable to invest into molecules in the503
early stages of drug discovery. Besides having economical profitability, it is504
often the case that a budget for drug discovery is made available in research505
projects to stimulate medical innovation.506
Fifth, for the fixed size portfolio model, we assume that 100 molecules507
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need to be selected out of each dataset into the portfolio of molecules to be508
tested in vitro: NPortfolio = 100.509
Sixth, the budget to be spent and to be taken into account as a constant in510
the model is calculated assuming a fixed number of molecules NPortfolio = 100511
will be bought. Hence, the budget can be obtained as an average cost512
multiplied by the number of molecules to be bought: B = NPortfolio ∗513 ∑NTotal
i=1 ci/NTotal.514
Seventh, the budget is set to a hundred times the average cost of molecules515
in the dataset: B = 100∗ c̄. For the dataset of 1000 molecules this yields B =516
34, 502USD, for the dataset of 2500 molecules this yields B = 34, 400USD517
and for the dataset of 5000 molecules this results in B = 34, 622USD.518
Eighth, based on comparison of performance of the algorithms on all three519
datasets, it was observed that larger datasets perform better, when compared520
to smaller datasets, assuming the same fixed number of 100 molecules is521
selected from all three datasets. One could argue that this may be the result522
of applying more iterations in the bigger datasets. However, this is not523
the case as all datasets converge after 100, 000 iterations, which means that524
running the algorithms for more iterations will not be effective.525
The reason for this behavior is the way success probabilities of molecules526
are computed: The success probability of a molecule is calculated inversely527
proportional to average activity of all molecules belonging to the dataset.528
It would be a correct approach if the datasets would be uniformly selected529
from the vendor database. However, in our case the datasets were sorted by530
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activity before selection and from the same sorted dataset top 1000, 2500 and531
5000 most active molecules were selected. The datasets are sorted based on532
activity because chemists usually do not consider molecules below the cut-off533
activity. Thus, larger datasets, e.g. with 2500 and 5000 molecules, contain534
molecules with lower activity on average, when compared to smaller datasets535
with higher average activity, e.g. with 1000 molecules.536
To avoid the situation when the average success probability of a given537
molecule is lower in a bigger dataset when compared to the average suc-538
cess probability of the same molecule in a smaller dataset, its calculation is539
adjusted. In particular, the average probability of success of a molecule is540
computed in such a way that it is independent of the size of the considered541
dataset, and in such a way it suits better to datasets with a non-uniform542
distribution of activities.543
As before it is assumed that success probability is proportional to the ac-544
tivity. However, now the average probability p̄1000 is fixed to be proportional545
to the average activity ā1000 of the 1000 molecules dataset:546
p̄1000 = k ∗ ā1000, ∀i = {1, . . . , NTotal}. (14)
which leads to the k computed as:547





Thus, the probability of success of each molecule can be computed as:548




Hence, this fixed average probability p̄1000 of the 1000 molecules dataset will549
be used for computing the probabilities of success of molecules pi in the550
datasets with 2500 and 5000 molecules.551
5.2. Molecular compounds datasets552
For testing efficiency of the proposed models for molecule subset selection,553
we have used 3 datasets of 1000, 2500 and 5000 molecules taken from the554
ZINC database of molecular compounds (see [13]), as available at vendor555
Enamine. Each molecule was provided with its known structure and its556
cost per 100mg. The Tanimoto similarity was calculated for each pair of557
molecules.558
These three datasets are demonstrated in Figure 2 (a) with activity and559
cost of the 1000 molecules set depicted in (dark) green, the 2500 molecules560
set depicted in green and (light) pink, and the 5000 molecules set depicted561
in green, pink and blue.562
5.3. Experimental settings for MOEAs563
In the experiments of this study, the following settings are used: pMA =564
0.5 (per portfolio), pMD = 0.1 (per portfolio), and pMR = 0.01 (per molecule).565
The number of crossover points was set to 1, and the probability of crossover566
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(a) (b)
Figure 2: (a) Cost and activity of molecules in three data sets. (b) Size of the population
of portfolios in a single run (depicted in a circle) of SMS-EMOA for three data sets
was set to pCO = 0.2. In other words, for every 10 offspring there are 2 that567
have been created using 2 parents, while the other 8 offspring are copies of568
some parents. Replacing a molecule in the portfolio with pMR = 0.01 means569
replacing one molecule per offspring on average. A molecule is added to half570
of the offspring on average: pMA = 0.5, and is removed from a portfolio571
once per 10 offspring on average: pMD = 0.1. The size of the population of572
portfolios P (t), t = 1, 2, . . . was set to 10 in order to conform with the setting573
we used to sample the Pareto front by means of quadratic programming.574
For fair comparison of MOEAs, in all experiments we run NSGA-II for575
10, 000 iterations and SMS-EMOA for 100, 000 for the dataset of 1000 molecules.576
This is due to the fact that SMS-EMOA creates 1 offspring at each iter-577
ation, whereas NSGA-II creates 100 offspring at each iteration. For the578
larger datasets, we increased the number of iterations with the same factor579
as the dataset size. That is, for the 2500 molecules dataset we ran NSGA-580
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II for 25, 000 iterations and SMS-EMOA for 250, 000 iterations, whereas for581
the 5000 molecules dataset, we ran NSGAII for 50, 000 iterations and SMS-582
EMOA for 500, 000 iterations.583
Due to the design of mutation operator used in this work, which allows not584
only replacing molecules in portfolio, but also adding or removing portfolios585
in the population, the population size varies. Figure 2 (b) gives insight into586
the cardinality of the sets of portfolios in the population obtained after a587
typical run of MOEAs (SMS-EMOA in this case, but similar results were588
obtained for NSGA-II).589
A problem with the model (2) that minimizes risk without a cardinality590
constraint can be observed. In particular, this model allows selection of very591
small subsets of portfolios, and even the empty set of portfolios, as a part of592
the optimal front. Given the model this makes sense as there is no subset of593
portfolios with a higher return other than the one with a variance of 0USD.594
However, in practice this is undesirable.595
5.4. Discussion of the experimental results596
We tested the portfolio selection problem models formulated in sections597
2 and 3 with the algorithms presented in section 4 on all three datasets598
discussed above.599
All experiments were performed on a desktop PC with an i5 core 3.2 GHz600
processor and 4 GB memory under Windows XP operating system. Gurobi601
MIP solver version 4.0 was used and MOEAs were encoded in Python version602
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3.3.603
5.4.1. Markowitz model with fixed portfolio size604
Gurobi MIP results In the first experiment we computed Pareto front605
of portfolios optimal from the point of view of their return and risk according606
to the Markowitz model with fixed size portfolios (NPortfolio = 100) using the607
formulation (6) as discussed in section 2.2. Here it is assumed that probability608
of success for each molecule is proportional to its activity and is computed609
by (11), and covariance between molecules is computed based on a distance610
as defined in (9).611
The ε-constraint approach to MOO was used. In particular, the return612
objective was set to a constraint (computed for 15 different points between613
lower and upper return bounds, Emin and Emax, respectively) and Gurobi614
MIP solver utilizing branch and bound method was applied to the three615
datasets with 1000, 2500 and 5000 molecules. The results of runs for all616
three datasets are presented in Figures 4 (a), (b) and (c), respectively, in617
black color.618
Next, we analyze the content of portfolios belonging to the Pareto front619
of optimal portfolios with 100 molecules selected in each portfolio using the620
dataset with 2500 molecules as an example. In particular, we show four621
heat-maps indicating the similarity of selected molecules for portfolios with622
three different return values equal to 0USD, 1104USD and 1449USD and623
one randomly selected portfolio of 100 molecules demonstrated in Figure 3624
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(a), (b), (c) and (d), respectively. (Random selection was performed using a625
random percent filter in Pipeline Pilot using seed 333.) The darker the color626
the more similar the molecules are: the blue color gradient corresponds to a627
similarity equal to 1, dodger-blue to a similarity equal to 0.5, and white to a628
similarity equal to 0.629
When compared to the baseline portfolio with 100 randomly selected630
molecules depicted in Figure 3 (d), the portfolio with 0USD return value631
depicted in Figure 3 (a) looks much more diverse, the portfolio with 1104USD632
return value depicted in Figure 3 (b) is slightly more diverse, and the portfolio633
with 1449USD return value depicted in Figure 3 (c) is much less diverse.634
The portfolio with 1104USD return value shown in Figure 3 (b) shows better635
diversity when compared to the baseline and relatively high return portfolios,636
being either close to or exactly the portfolio with optimal Sharpe ratio. This637
output is in line with the portfolio selection theory, according to which higher638
return portfolios are less diverse, since they also have higher risk, and the639
lower return portfolios are more diverse and have lower risk.640
MOEAs results Comparison of MOEAs results is not trivial: On the641
one hand, due to the randomness of the population initialization and of the642
application of the crossover and mutation operators for individuals of the643
population, not a single run, but some averaged performance of MOEAs’644
several runs should be compared for evaluating performance of each MOEA.645
On the other hand, comparison of the convergence of each algorithm is dif-646
ficult due to the fact that no true Pareto front is known. Therefore, only647
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Figure 3: Similarity of 100 molecules portfolios belonging to the Pareto front and selected
from the set of 2500 molecules with (a) 0USD return, (b) 1104USD return, (c) 1449USD
return and (d) portfolio with 100 randomly selected molecules.
a visual comparison can be made based on the attainment surfaces [9] (or648
attainment curves for bi-objective optimization, which is our case) covered649
by each MOEA. This approach allows the comparison of lowest and highest650
Pareto front solutions achieved by each algorithm as well as their average651
performances. For computing the attainment surface a generalization of the652
median as an average is used, which is robust against outliers. In the next ex-653
periments only best front is taken from all runs of an algorithm for comparing654
to other algorithms performance.655
Comparison of Gurobi MIP solver and MOEAs result: We com-656
pared results obtained by the Gurobi MIP solver using branch and bound657
method to the results obtained by two MOEAs, NSGA-II and SMS-EMOA.658

















































Figure 4: Comparison of the performance of the Gurobi MIP solver and the two MOEAs:
NSGA-II and SMS-EMOA (on the plot denoted as QP, NSGA avg and SMS avg, respec-
tively) for the 1000, 2500, 5000 molecules dataset, (a) (b) and (c), respectively.
dataset with 1000 molecules, for circa 20 minutes for the dataset with 2500660
molecules, and for circa 30 minutes for the dataset with 5000 molecules.661
The results of this comparison presented in Figures 4 (a), (b) and (c) show662
the best performance of the exact Gurobi MIP solver for the datasets with663
1000 and 5000 molecules, and better performance of the SMS-EMOA when664
compared to NSGA-II on all three datasets. As can be seen from Figure 4665
(b) in some concave regions of the Pareto front SMS-EMOA outperformed666
Gurobi MIP solver, which means that specified time limit was not sufficient667
for branch and bound method of Gurobi MIP solver to find optimal solution.668
5.4.2. Sharpe ratio with fixed portfolio size669
We now show and discuss the results obtained for model (3). Figure 5 (a)670
demonstrates values of Sharpe ratio computed for 100 molecules selected from671
the 1000-molecule dataset at each of the 15th iterations of the ε-constraint672
method. These portfolios belong to the Pareto front of optimal portfolios673
and are obtained with the Gurobi MIP solver. In this case the portfolio674
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(a) (b)
Figure 5: (a) Sharpe ratios of 15 portfolios of 100 molecules belonging to the Pareto front
and selected from the set of 1000 molecules. (b) Prices and activities of the 1000 dataset
molecules (in red) and of the Sharpe optimal portfolio molecules (in black).
obtained at the 13th iteration has the highest Sharpe ratio value and should675
be selected as the most promising one for potential drug discovery. Next, we676
will analyze the content of this portfolio.677
In Figure 5 (b), the molecules of the 1000 dataset are presented. Here,678
the molecules are allocated according to their activity (see X-axis) and price679
(see Y-axis), respectively. The molecules selected in the Sharpe optimal680
portfolio are marked in red and the non-selected molecules are depicted in681
black. As can be observed from this figure, not only the cheapest molecules682
are selected and not only the most active ones, but some balance between683
price and activity is reached for the portfolio of molecules as a whole.684
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(a) (b) (c)
Figure 6: Comparison of NSGA-II and SMS-EMOA for Solow-Polasky diversity model
with 1000, 2500 and 5000 molecules dataset, (a), (b), and (c), respectively.
5.4.3. Markowitz model with Solow-Polasky diversity685
We now show and discuss the results obtained for model (5). Note that686
these results are for MOEAs only, as application of the MIP solver is com-687
plicated due to the need of obtaining the inverse of distance matrix.688
Comparison of Pareto fronts obtained by NSGA-II and SMS-EMOA for689
Solow-Polasky diversity model provided in Figures 6 (a), (b), and (c) for690
datasets with 1000, 2500 and 5000 molecules, respectively, show outperfor-691
mance of SMS-EMOA when compared to NSGA-II.692
The formulation of the Solow Polasky diversity measure includes the in-693
version of a matrix making it difficult to optimize this measure by means694
of an exact solver, unlike the Sharpe ratio maximization formulation, which695
can be solved by quadratic programming. However, it might be possible to696
construct an approximation algorithm with an exact error bound for com-697
puting Solow Polasky diversity measure. Based on numerical experiments we698
conjecture that the Solow Polasky diversity is a submodular set function. If699
this is true, a greedy subset selection heuristic would yield an approximation700
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with approximation ratio (1 − 1/e). We were not able to provide a formal701
proof for submodularity and leave this question to the future work.702
6. Conclusion and future research703
In this work, we presented a new approach to formulating the selection704
of molecules for de-novo drug discovery. In particular, the well-known in705
finance portfolio-based approach was used to model molecular subset selec-706
tion for drug discovery as a portfolio selection. In addition to taking into707
account (bio-)activity of the molecules selected in the portfolio, the model708
considers the diversity of such portfolio. Moreover, it respects the limited709
budget provided for buying molecules and the fixed size of the portfolio as710
constraints. Molecules selected in the portfolio are balanced in terms of their711
price, expected individual performance and diversity.712
Three models were proposed and tested on three molecular compounds713
datasets, in particular, classical Markowitz portfolio selection model, Sharpe714
ratio optimization and diversity optimization models. For solving Markowitz715
model with fixed size portfolio that optimizes return and risk simultaneously,716
we used ε-constrained approach in combination with Gurobi MIP solver and717
applied approximation approaches, in particular, multiobjective evolution-718
ary algorithms, NSGA-II and SMS-EMOA. As expected QP solver was most719
efficient in calculating Pareto fronts except for some parts, which is due to a720
QP’s fixed exploration time threshold. SMS-EMOA outperformed NSGA-II721
for Markowitz portfolio selection model. For the single objective Sharpe ratio722
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maximization model we adjusted Gurobi MIP solver and analyzed content723
of the selected optimal portfolios. Finally, for solving diversity optimization724
model only approximate algorithms, NSGA-II and SMS-EMOA, were used,725
with SMS-EMOA performing better than NSGA-II on all datasets. Solv-726
ing this model with a quadratic solver requires obtaining inverse of distance727
matrix, which is difficult in practice as initial research shown. The pre-728
sented preliminary test results of these novel formulations obtained for three729
molecular compounds datasets look promising and encourage us to do future730
research.731
We have also discerned a number of future research topics that could be732
investigated further. In particular, different formulations of risk could be733
tested. For instance, other popular risk measures, such as Value-at-Risk (or734
return-to-standard deviation index) and the diversity inversely proportional735
to the number of species in the population can be investigated further. It736
would also be interesting to construct Sharpe ratio as a tangential point to737
the Pareto front (with CAL) and directly compute the Sharpe ratio opti-738
mum via homogenization. As the initial trials indicated the later approach739
is really challenging, but it might turn out to be easier for alternative risk740
formulations. Furthermore, alternative diversity measures, e.g. Weitzman741
diversity [28], can be considered in optimization models. A sensitivity analy-742
sis for some parameters of the models (e.g., theta parameter in Solow-Polasky743
diversity measure) will be of value for the proposed portfolio approach.744
Current results show that application of existing QP solvers to large size745
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problems (bigger than 5000 molecules) is difficult due to large run times. To746
improve exact solvers’ performance for large models, relaxation of integrity747
constraints can be applied. This would lead to rounding-off running time to748
polynomial, but will require covariance matrix to be positive definite. Alter-749
natively, a MOEA could be used for preselection and QP solver for the final750
portfolio selection. It should be noted, however, that it takes approximately751
10 minutes for SMS-EMOA to find Pareto front of portfolios for a dataset752
of 1000 molecules. Hence, in this case either parallelization or fast heuristic753
filters can be used for preselection as well.754
An important task for future work is not only to scale up the models755
proposed in this work for larger portfolios, but also to further investigate the756
availability of exact solvers and performance for smaller portfolios. Moreover,757
experience with actual performance of the models in drug discovery practice758
needs to be assessed by comparing data of outcomes of a larger number of759
in vitro drug discovery studies with what has been predicted by the models.760
In this work, only structural similarity of molecules was taken into ac-761
count. Recent research [19] has shown that biological similarity plays an762
important roles in comparison of molecules. Similarly to structural diversity,763
biological diversity can be maximized as a third objective in the last pro-764
posed model. Two other models can also be adjusted to take into account765
biological similarity in the risk calculation. Moreover, at the later stages of766
drug discovery process additional objectives can be considered for molecular767
portfolio selection, such as minimizing side effects of the discovered lead can-768
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didates. The experimental validation of the discovered molecular portfolio769
via in vitro testing and chemists feedback on the results of such testing will770
be a natural next stage for the proposed in this work molecular portfolio771
selection approach.772
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